Cell therapy steps closer to commercial reality
Uncategorized
THE Cell Therapy Manufacturing Cooperative Research Centre (CTMCRC) based in South Australia has confirmed its first commercial transfer of intellectual property to Terumo BCT Australia Ltd.
Sign up to receive notifications about new stories in this category.
Thank you for subscribing to story notifications.
The CTMCRC explores cell therapy manufacturing techniques in an attempt to commercialise novel treatment techniques for previously incurable conditions such as type 1 diabetes, diabetic wounds, and immune-mediated diseases.
South Australian Health Industries Minister Jack Snelling said the IP transfer vindicates the Research Centre's efforts in making treatments affordable and accessible.
“This latest achievement adds to the state's reputation for health and biomedical research and innovation and complements one of the largest health precincts in the Southern Hemisphere, the South Australian Health and Biomedical Precinct,” Minister Snelling said.
“It's important that research is commercialised to accelerate the development and delivery of world-class healthcare and also to open the door to new industries.”
To mark these developments, the CTMCRC will conduct a symposium in the auditorium of the South Australian Health and Medical Research Institute (SAHMRI) tonight.
The symposium will raise the profile of cell therapies in Australia, promote the work of the CTMCRC, and publicise its commercial association with TerumoBCT which participates in the CRC.
A panel of experts will be at the symposium including:
Mr Chockalingam Palaniappan (Palani) – Senior Vice President of TerumoBCT; Professor John Rasko – one of Australia’s leading clinician in cell therapies from the Royal Prince Alfred Hospital; Professor Leanna Read – Chief Scientist for South Australia; and Professor Rob Short – Pro-Vice Chancellor, UniSA
Jump to next article
